Your browser is no longer supported. Please, upgrade your browser.
HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite Help
publish chart | save to portfolio | create alert Type: candle | line | advanced | interactive | perf    Timeframe: intraday | daily | weekly | monthly  Settings
PLX [AMEX]
Protalix BioTherapeutics, Inc.
Healthcare | Biotechnology | Israel
statements
Index- P/E- EPS (ttm)-0.39 Insider Own22.48% Shs Outstand45.38M Perf Week-0.63%
Market Cap71.25M Forward P/E39.25 EPS next Y0.04 Insider Trans-8.26% Shs Float34.67M Perf Month-15.59%
Income- PEG- EPS next Q-0.08 Inst Own20.94% Short Float6.02% Perf Quarter-74.76%
Sales52.57M P/S1.36 EPS this Y-95.50% Inst Trans- Short Ratio0.91 Perf Half Y-65.72%
Book/sh0.32 P/B4.91 EPS next Y109.30% ROA- Target Price- Perf Year-57.57%
Cash/sh- P/C- EPS next 5Y25.00% ROE- 52W Range1.46 - 7.02 Perf YTD-56.75%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-77.64% Beta-
Dividend %- Quick Ratio- Sales past 5Y- Gross Margin- 52W Low7.53% ATR0.11
Employees207 Current Ratio- Sales Q/Q-47.70% Oper. Margin- RSI (14)33.44 Volatility8.81% 6.40%
OptionableYes Debt/Eq- EPS Q/Q- Profit Margin- Rel Volume0.33 Prev Close1.67
ShortableYes LT Debt/Eq- EarningsMay 14 BMO Payout- Avg Volume2.30M Price1.57
Recom2.00 SMA20-10.16% SMA50-27.94% SMA200-57.80% Volume752,448 Change-5.99%
Jun-08-20Reiterated H.C. Wainwright Buy $3 → $11
Apr-17-17Reiterated Rodman & Renshaw Buy $4 → $5
Apr-04-16Initiated Rodman & Renshaw Buy $3.50
Apr-23-15Upgrade Jefferies Hold → Buy $2 → $2.60
Nov-12-14Reiterated R. F. Lafferty Buy $8 → $5
Jan-24-14Initiated R. F. Lafferty Buy $8
May-02-12Reiterated Oppenheimer Outperform $9 → $11
May-02-12Downgrade Canaccord Genuity Buy → Hold $8 → $8
Apr-30-12Downgrade Auriga Buy → Hold $8 → $8
Oct-13-11Initiated Morgan Joseph Hold
Mar-17-11Downgrade WBB Securities Strong Buy → Buy $10
Nov-09-10Reiterated Oppenheimer Outperform $10 → $12
Oct-14-10Reiterated UBS Buy $9 → $10.75
Dec-02-09Reiterated Hapoalim Outperform $10 → $12
Sep-22-09Initiated Canaccord Adams Buy
Sep-02-09Initiated Hapoalim Outperform $10
Dec-01-08Reiterated Oppenheimer Outperform $6 → $4
Mar-11-08Initiated UBS Buy $6
Nov-20-07Initiated CIBC Wrld Mkts Sector Outperform $7
Jun-30-21 09:56AM  
Is Protalix BioTherapeutics Inc. (PLX) A Good Stock To Buy?
Insider Monkey
Jun-28-21 06:50AM  
Protalix BioTherapeutics to Participate in a Fireside Chat on June 30, 2021
PR Newswire
Jun-07-21 10:18PM  
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Protalix BioTherapeutics, Inc. - PLX
GlobeNewswire
Jun-05-21 08:16PM  
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Protalix BioTherapeutics, Inc. - PLX
Newsfile
Jun-03-21 09:28AM  
PLX: BALANCE: Interim Results
Zacks Small Cap Research -10.48%
09:28AM  
PLX: BALANCE: Interim Analysis
Zacks Small Cap Research
12:30AM  
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Protalix BioTherapeutics, Inc. - PLX
PR Newswire
Jun-02-21 12:10PM  
Protalix Shares Hits 52-Week Low After Adverse Event Reported In Fabry Disease Trial With PRX-102
Benzinga -16.78%
06:50AM  
Protalix Biotherapeutics and Chiesi Global Rare Diseases Provide Update Regarding Clinical Development of PRX-102 for Treatment of Fabry Disease
PR Newswire
May-25-21 06:50AM  
PLX: 1Q:21 Results & Next Steps
Zacks Small Cap Research
May-14-21 06:50AM  
Protalix BioTherapeutics Reports First Quarter 2021 Financial Results and Business Update
PR Newswire
06:45AM  
Protalix Biotherapeutics, Inc. to Host Earnings Call
ACCESSWIRE
May-07-21 10:30AM  
Protalix BioTherapeutics to Hold First Quarter 2021 Financial and Business Results Conference Call on May 14, 2021
PR Newswire
Apr-29-21 05:45AM  
PLX: Pandemic Backup Impedes FDA Site Survey
Zacks Small Cap Research -9.92%
Apr-28-21 03:25PM  
Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Protalix BioTherapeutics, Inc. (PLX) Investigation
ACCESSWIRE -32.59%
01:44PM  
Why Protalix BioTherapeutics Stock Is Plunging Today
Motley Fool
01:27PM  
Protalix BioTherapeutics Provides Update on Complete Response Letter for Pegunigalsidase Alfa from the FDA
PR Newswire
06:21AM  
Protalix Stock Falls After FDA Slaps CRL For PRX-102 Application In Fabry Disease
Benzinga
01:50AM  
Protalix BioTherapeutics and Chiesi Global Rare Diseases Receive Complete Response Letter for Pegunigalsidase Alfa from FDA
PR Newswire
Apr-07-21 05:15AM  
PLX: Target Action Date Four Weeks Away
Zacks Small Cap Research
Mar-30-21 06:50AM  
Protalix BioTherapeutics Reports Fiscal Year 2020 Financial and Business Results
PR Newswire
06:30AM  
Protalix Biotherapeutics, Inc. to Host Earnings Call
ACCESSWIRE
Mar-22-21 06:50AM  
Protalix BioTherapeutics to Hold Fiscal Year 2020 Financial and Business Results Conference Call on March 30, 2021
PR Newswire +6.67%
Mar-04-21 06:50AM  
Protalix BioTherapeutics to Present at the H.C. Wainwright Global Life Sciences Conference
PR Newswire -11.21%
Feb-24-21 08:03AM  
PLX: A Busy Month
Zacks Small Cap Research +11.33%
Feb-23-21 08:04AM  
Protalix's PRX102 Monthly Treatment Shows Benefit In Fabry Disease
Benzinga
07:25AM  
The Daily Biotech Pulse: Aridis To Study Antibody Cocktail For Coronavirus Variants, Revance & Protalix Data Readouts
Benzinga
06:50AM  
Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce Positive Topline Results from BRIGHT Phase III Open-Label, Switch-Over Clinical Trial Evaluating Pegunigalsidase Alfa 2 mg/kg every Four Weeks for Treatment of Fabry Disease
PR Newswire
Feb-22-21 03:20AM  
Protalix BioTherapeutics, Inc. (NYSEMKT:PLX) Is About To Turn The Corner
Simply Wall St.
Feb-18-21 08:02AM  
Protalix BioTherapeutics Completes Raise of Approximately $40 Million in Gross Proceeds
PR Newswire
Feb-12-21 05:54AM  
Protalix BioTherapeutics Raises $35M Via Equity At 21% Discount
Benzinga -15.37%
Feb-11-21 09:16PM  
Protalix BioTherapeutics Announces Pricing of its Upsized Public Offering of Common Stock
PR Newswire
04:35PM  
Protalix BioTherapeutics Announces Proposed Public Offering of Common Stock
PR Newswire
07:47AM  
Protalix BioTherapeutics Perks Up On Alidornase Alfa Licensing Pact In Respiratory Conditions
Benzinga
07:26AM  
The Daily Biotech Pulse: DermTech Soars On Contract, Fluidigm Plunges On Earnings, Decision Day For Regeneron, Bioventus Debuts
Benzinga
06:50AM  
Protalix BioTherapeutics Enters into an Exclusive Partnership with SarcoMed USA to Develop alidornase alfa for the Treatment of Pulmonary Sarcoidosis and Related Respiratory Diseases Via Inhaled Delivery
PR Newswire
Feb-10-21 07:01AM  
Protalix BioTherapeutics and Chiesi Global Rare Diseases Present Key Clinical Data of Pegunigalsidase Alfa for the Treatment of Fabry Disease at the 17th Annual WORLDSymposium 2021
PR Newswire -10.85%
Feb-01-21 06:50AM  
Protalix BioTherapeutics Announces Presentations at the 17th Annual WORLDSymposium 2021
PR Newswire
Jan-04-21 06:50AM  
Protalix BioTherapeutics to Participate in Upcoming Investor Conferences in January
PR Newswire
04:25AM  
PLX: Final Results for BRIDGE and A Letter to Shareholders
Zacks Small Cap Research
Dec-30-20 06:50AM  
Protalix BioTherapeutics Issues 2020 Letter to Shareholders
PR Newswire
06:00AM  
Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce Final Results of BRIDGE Phase III Open-Label, Switch-Over Clinical Trial Evaluating Pegunigalsidase Alfa for the Treatment of Fabry Disease
PR Newswire
Dec-21-20 06:40AM  
Have Insiders Been Buying Protalix BioTherapeutics, Inc. (NYSEMKT:PLX) Shares This Year?
Simply Wall St.
Dec-15-20 07:15AM  
PLX: FDA Approval To Start New Chapter
Zacks Small Cap Research +5.90%
Nov-30-20 03:38PM  
Is Protalix BioTherapeutics Inc. (PLX) A Good Stock To Buy Now?
Insider Monkey
Nov-27-20 06:50AM  
Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce Extension of PDUFA Date for Pegunigalsidase Alfa for the Proposed Treatment of Fabry Disease
PR Newswire -5.97%
Nov-05-20 06:50AM  
Protalix BioTherapeutics to Present at the H.C. Wainwright 6th Annual Israel Conference
PR Newswire
Oct-29-20 01:33PM  
Protalix BioTherapeutics to Reschedule Third Quarter 2020 Financial Results and Business Update Call for Friday, October 30
PR Newswire -5.63%
06:50AM  
Protalix BioTherapeutics Reports Third Quarter 2020 Financial Results and Provides Business Update
PR Newswire
06:30AM  
Protalix Biotherapeutics, Inc. to Host Earnings Call
ACCESSWIRE
Oct-26-20 06:50AM  
Protalix BioTherapeutics to Participate in Virtual Investor KOL Roundtable
PR Newswire
Oct-22-20 06:50AM  
Protalix BioTherapeutics to Hold Third Quarter 2020 Financial Results and Business Update Conference Call on October 29, 2020
PR Newswire
Oct-20-20 12:13PM  
Do Institutions Own Protalix BioTherapeutics, Inc. (NYSEMKT:PLX) Shares?
Simply Wall St.
Oct-02-20 08:00AM  
Chiesi Global Rare Diseases and Protalix BioTherapeutics Announce Launch of Expanded Access Program in the United States for Pegunigalsidase Alfa for the Proposed Treatment of Fabry Disease
PR Newswire
Sep-08-20 06:55AM  
Protalix BioTherapeutics Regains Compliance with NYSE American Continued Listing Standards
PR Newswire
06:45AM  
Protalix BioTherapeutics to Present in the H.C. Wainwright 22nd Annual Global Investment Virtual Conference
PR Newswire
Aug-24-20 06:50AM  
Protalix BioTherapeutics Announces Completion of the Treatment Period for its Phase III BRIGHT Clinical Trial of Pegunigalsidase Alfa (PRX-102) for the Proposed Treatment of Fabry Disease
PR Newswire
Aug-20-20 03:44PM  
Loss-Making Protalix BioTherapeutics, Inc. (NYSEMKT:PLX) Expected To Breakeven
Simply Wall St.
Aug-11-20 06:50AM  
Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce U.S. Food and Drug Administration Acceptance of Biologics License Application (BLA) for Pegunigalsidase Alfa for the Proposed Treatment of Fabry Disease and Grants Priority Review
PR Newswire
Aug-10-20 06:50AM  
Protalix BioTherapeutics Reports Second Quarter 2020 Financial Results and Provides Business Update
PR Newswire
Aug-06-20 01:02PM  
Protalix BioTherapeutics to Present at the BTIG Virtual Biotechnology Conference 2020
PR Newswire
Aug-03-20 09:13AM  
Protalix BioTherapeutics to Hold Second Quarter 2020 Financial Results and Business Update Conference Call on August 10, 2020
PR Newswire
Jul-23-20 02:29PM  
Protalix BioTherapeutics Enters into Non-Binding Term Sheet with SarcoMed USA to Develop alidornase alfa for the Treatment of Pulmonary Sarcoidosis and Related Diseases
PR Newswire
Jul-22-20 07:28PM  
Edited Transcript of PLX.A earnings conference call or presentation 1-Jun-20 12:30pm GMT
Thomson Reuters StreetEvents
Jun-18-20 12:20PM  
Have Insiders Been Buying Protalix BioTherapeutics, Inc. (NYSEMKT:PLX) Shares?
Simply Wall St. +9.57%
Jun-08-20 05:00PM  
Protalix BioTherapeutics Appoints Yael Hayon, Ph.D. as its New Vice President, Research and Development
PR Newswire +7.24%
Jun-03-20 08:46PM  
Edited Transcript of PLX earnings conference call or presentation 12-Mar-20 12:30pm GMT
Thomson Reuters StreetEvents
Jun-01-20 06:50AM  
Protalix BioTherapeutics Reports First Quarter 2020 Financial Results and Business Update
PR Newswire
06:30AM  
Protalix Biotherapeutics, Inc. to Host Earnings Call
ACCESSWIRE
May-29-20 09:43AM  
Protalix Submits BLA for Fabry Disease Candidate PRX-102
Zacks -5.92%
May-28-20 06:50AM  
Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce Submission of Biologics License Application to U.S. Food and Drug Administration for Pegunigalsidase Alfa for the Treatment of Fabry Disease
PR Newswire
May-22-20 04:05PM  
Protalix BioTherapeutics to Hold First Quarter 2020 Financial Results and Business Update Conference Call on June 1, 2020
PR Newswire
May-11-20 06:50AM  
Protalix BioTherapeutics Announces Positive Topline Results from the BRIDGE Phase III Open-Label, Switch-Over Clinical Trial Evaluating Pegunigalsidase Alfa for the Treatment of Fabry Disease
PR Newswire +5.31%
Mar-18-20 12:12PM  
Protalix BioTherapeutics Announces Closing of $43.7 Million Private Placement
PR Newswire
Mar-16-20 06:50AM  
Protalix Biotherapeutics Announces Feasibility Study with Kirin Holdings on the Production of a Novel Complex Protein
PR Newswire -8.30%
Mar-12-20 08:04AM  
Protalix BioTherapeutics Reports Fourth Quarter and Full Year 2019 Financial and Business Results
PR Newswire
07:55AM  
Protalix BioTherapeutics Announces $43.7 Million in Financing to Further Advance its Programs in Fabry Disease
PR Newswire
Mar-05-20 07:00AM  
Protalix BioTherapeutics to Hold Fourth Quarter and Full-Year 2019 Financial and Business Results Conference Call on March 12, 2020
PR Newswire
Feb-11-20 10:52AM  
Protalix BioTherapeutics, Inc.'s (NYSEMKT:PLX) Profit Outlook
Simply Wall St.
Feb-10-20 04:05PM  
Protalix BioTherapeutics Presents Key Clinical Data of Pegunigalsidase Alfa for the Treatment of Fabry Disease at the 16th Annual WORLDSymposium 2020
PR Newswire
Feb-06-20 06:50AM  
Protalix BioTherapeutics and Chiesi Farmaceutici Announce Receipt of "Agreement Letter" for Initial Pediatric Study Plan for PRX-102 for the Treatment of Fabry Disease
PR Newswire
Feb-04-20 09:00AM  
Protalix BioTherapeutics to Participate in the 2020 BIO CEO & Investor Conference and the Noble Capital Markets' 16th Annual Small & Microcap Investor Conference
PR Newswire
Jan-30-20 07:30AM  
Protalix BioTherapeutics to Participate in the 16th Annual WORLDSymposium 2020
PR Newswire
Jan-14-20 05:09PM  
Seattle Seahawks' top 10 plays | 2019 season
NFL Highlights -7.87%
Dec-19-19 06:50AM  
Protalix BioTherapeutics Adds Two Accomplished Biopharmaceutical Executives to its Board of Directors
PR Newswire
Dec-09-19 04:05PM  
Protalix BioTherapeutics Announces 1-for-10 Reverse Stock Split
PR Newswire
Nov-29-19 10:37PM  
Hedge Funds Watching Protalix BioTherapeutics Inc. (PLX) From Afar
Insider Monkey +8.78%
Nov-27-19 06:50AM  
Protalix BioTherapeutics Hosting Key Opinion Leader Meeting on PRX102 Drug Candidate for the Treatment of Fabry Disease
PR Newswire +6.76%
12:11AM  
Edited Transcript of PLX earnings conference call or presentation 7-Nov-19 1:30pm GMT
Thomson Reuters StreetEvents
Nov-19-19 09:26AM  
Protalix Finalizes Accelerated Approval Pathway for PRX-102
Zacks -7.83%
Nov-18-19 06:50AM  
Protalix BioTherapeutics and Chiesi Farmaceutici Announce Successful pre-BLA Meeting with FDA for Accelerated Approval of pegunigalsidase alfa for the Treatment of Fabry Disease in the United States
PR Newswire +32.31%
Nov-13-19 11:59AM  
Some Protalix BioTherapeutics (NYSEMKT:PLX) Shareholders Have Taken A Painful 90% Share Price Drop
Simply Wall St.
Nov-07-19 09:25AM  
Protalix (PLX) Reports Q3 Loss, Tops Revenue Estimates
Zacks
06:50AM  
Protalix BioTherapeutics Reports Third Quarter 2019 Results and Provides Corporate Update
PR Newswire
Oct-31-19 10:34AM  
Protalix (PLX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Zacks -9.38%
Oct-29-19 07:00AM  
Protalix BioTherapeutics to Release Third Quarter 2019 Financial Results and Business Update on November 7, 2019
PR Newswire
Oct-17-19 07:40AM  
Protalix BioTherapeutics Announces Positive 12-Month Interim Data From the BRIDGE Phase III Open Label Switch-over Study of Pegunigalsidase Alfa for the Treatment of Fabry Disease
PR Newswire +74.03%
Sep-25-19 06:22PM  
Protalix Completes Enrollment in Third Fabry Disease Study
Zacks +8.75%
Sep-24-19 07:00AM  
Protalix BioTherapeutics and Chiesi Group Complete Enrollment in the Third Phase III Clinical Trial of pegunigalsidase alfa (PRX102) for the Treatment of Fabry Disease
PR Newswire
Sep-02-19 11:40AM  
Edited Transcript of PLX earnings conference call or presentation 8-Aug-19 12:30pm GMT
Thomson Reuters StreetEvents
Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in Israel, Brazil, rest of Latin America, and internationally. The company offers Elelyso for the treatment of Gaucher disease. Its product pipeline comprises PRX-102, a therapeutic protein candidate, which is in phase III clinical trials for the treatment of Fabry diseases; PRX-110, a proprietary plant cell recombinant form of human deoxyribonuclease I that has completed phase IIa clinical trials for the treatment of cystic fibrosis; PRX-115, a plant cell-expressed recombinant PEGylated Uricase for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundacao Oswaldo Cruz (Fiocruz); and Chiesi Farmaceutici S.p.A. The company was founded in 1993 and is headquartered in Karmiel, Israel.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Dexcel Pharma Technologies Ltd10% OwnerJun 03Sale2.25857,5061,932,3043,637,314Jun 03 05:40 PM
Dexcel Pharma Technologies Ltd10% OwnerJun 02Sale2.5661,211156,5534,494,820Jun 03 05:40 PM
open in yahoo | open in reuters | open in marketwatch | open in google
affiliate • advertise • contact • privacy • help
Do not sell my personal information
Quotes delayed 15 minutes for NASDAQ, and 20 minutes for NYSE and AMEX.
Copyright © 2007-2021 FINVIZ.com. All Rights Reserved.